#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=It has been shown in cancer hyperthermia, that when the target tissues have been adequately treated even one or two times, they will completely respond.
1-1	0-2	It	_	_	
1-2	3-6	has	_	_	
1-3	7-11	been	_	_	
1-4	12-17	shown	_	_	
1-5	18-20	in	_	_	
1-6	21-27	cancer	_	_	
1-7	28-40	hyperthermia	_	_	
1-8	40-41	,	_	_	
1-9	42-46	that	_	_	
1-10	47-51	when	_	_	
1-11	52-55	the	_	_	
1-12	56-62	target	_	_	
1-13	63-70	tissues	_	_	
1-14	71-75	have	_	_	
1-15	76-80	been	_	_	
1-16	81-91	adequately	_	_	
1-17	92-99	treated	_	_	
1-18	100-104	even	_	_	
1-19	105-108	one	_	_	
1-20	109-111	or	_	_	
1-21	112-115	two	_	_	
1-22	116-121	times	_	_	
1-23	121-122	,	_	_	
1-24	123-127	they	_	_	
1-25	128-132	will	_	_	
1-26	133-143	completely	_	_	
1-27	144-151	respond	_	_	
1-28	151-152	.	_	_	

#Text=The response is normally measured by tissue necrosis.
2-1	153-156	The	_	_	
2-2	157-165	response	_	_	
2-3	166-168	is	_	_	
2-4	169-177	normally	_	_	
2-5	178-186	measured	_	_	
2-6	187-189	by	_	_	
2-7	190-196	tissue	_	_	
2-8	197-205	necrosis	_	_	
2-9	205-206	.	_	_	

#Text=These necrotic or dead tissues are normally absorbed and digested by the natural body process of removing dead cells.
3-1	207-212	These	_	_	
3-2	213-221	necrotic	_	_	
3-3	222-224	or	_	_	
3-4	225-229	dead	_	_	
3-5	230-237	tissues	_	_	
3-6	238-241	are	_	_	
3-7	242-250	normally	_	_	
3-8	251-259	absorbed	_	_	
3-9	260-263	and	_	_	
3-10	264-272	digested	_	_	
3-11	273-275	by	_	_	
3-12	276-279	the	_	_	
3-13	280-287	natural	_	_	
3-14	288-292	body	_	_	
3-15	293-300	process	_	_	
3-16	301-303	of	_	_	
3-17	304-312	removing	_	_	
3-18	313-317	dead	_	_	
3-19	318-323	cells	_	_	
3-20	323-324	.	_	_	

#Text=Thus, adequate treatment of the tissues within the prostate by even one good heat treatment of the entire target mass is expected to result in the full effect of therapy.
4-1	325-329	Thus	_	_	
4-2	329-330	,	_	_	
4-3	331-339	adequate	_	_	
4-4	340-349	treatment	_	_	
4-5	350-352	of	_	_	
4-6	353-356	the	_	_	
4-7	357-364	tissues	_	_	
4-8	365-371	within	_	_	
4-9	372-375	the	_	_	
4-10	376-384	prostate	_	_	
4-11	385-387	by	_	_	
4-12	388-392	even	_	_	
4-13	393-396	one	_	_	
4-14	397-401	good	_	_	
4-15	402-406	heat	_	_	
4-16	407-416	treatment	_	_	
4-17	417-419	of	_	_	
4-18	420-423	the	_	_	
4-19	424-430	entire	_	_	
4-20	431-437	target	_	_	
4-21	438-442	mass	_	_	
4-22	443-445	is	_	_	
4-23	446-454	expected	_	_	
4-24	455-457	to	_	_	
4-25	458-464	result	_	_	
4-26	465-467	in	_	_	
4-27	468-471	the	_	_	
4-28	472-476	full	_	_	
4-29	477-483	effect	_	_	
4-30	484-486	of	_	_	
4-31	487-494	therapy	_	_	
4-32	494-495	.	_	_	

#Text=This could reduce the number of required treatments from about ten to only one or two.
5-1	496-500	This	_	_	
5-2	501-506	could	_	_	
5-3	507-513	reduce	_	_	
5-4	514-517	the	_	_	
5-5	518-524	number	_	_	
5-6	525-527	of	_	_	
5-7	528-536	required	_	_	
5-8	537-547	treatments	_	_	
5-9	548-552	from	_	_	
5-10	553-558	about	_	_	
5-11	559-562	ten	_	_	
5-12	563-565	to	_	_	
5-13	566-570	only	_	_	
5-14	571-574	one	_	_	
5-15	575-577	or	_	_	
5-16	578-581	two	_	_	
5-17	581-582	.	_	_	

#Text=This could greatly reduce treatment costs and inconvenience.
6-1	583-587	This	_	_	
6-2	588-593	could	_	_	
6-3	594-601	greatly	_	_	
6-4	602-608	reduce	_	_	
6-5	609-618	treatment	_	_	
6-6	619-624	costs	_	_	
6-7	625-628	and	_	_	
6-8	629-642	inconvenience	_	_	
6-9	642-643	.	_	_	

#Text=The current methods using microwave urethra heating without cooling have been found to treat to a depth of about 0.6 cm and a length of about 4.5 cm.
7-1	644-647	The	_	_	
7-2	648-655	current	_	_	
7-3	656-663	methods	_	_	
7-4	664-669	using	_	_	
7-5	670-679	microwave	_	_	
7-6	680-687	urethra	_	_	
7-7	688-695	heating	_	_	
7-8	696-703	without	_	_	
7-9	704-711	cooling	_	_	
7-10	712-716	have	_	_	
7-11	717-721	been	_	_	
7-12	722-727	found	_	_	
7-13	728-730	to	_	_	
7-14	731-736	treat	_	_	
7-15	737-739	to	_	_	
7-16	740-741	a	_	_	
7-17	742-747	depth	_	_	
7-18	748-750	of	_	_	
7-19	751-756	about	_	_	
7-20	757-760	0.6	_	_	
7-21	761-763	cm	_	_	
7-22	764-767	and	_	_	
7-23	768-769	a	_	_	
7-24	770-776	length	_	_	
7-25	777-779	of	_	_	
7-26	780-785	about	_	_	
7-27	786-789	4.5	_	_	
7-28	790-792	cm	_	_	
7-29	792-793	.	_	_	

#Text=This results in a treated volume of about 9 cm.sup.3 for a mass of 9 grams.
8-1	794-798	This	_	_	
8-2	799-806	results	_	_	
8-3	807-809	in	_	_	
8-4	810-811	a	_	_	
8-5	812-819	treated	_	_	
8-6	820-826	volume	_	_	
8-7	827-829	of	_	_	
8-8	830-835	about	_	_	
8-9	836-837	9	_	_	
8-10	838-844	cm.sup	_	_	
8-11	844-846	.3	_	_	
8-12	847-850	for	_	_	
8-13	851-852	a	_	_	
8-14	853-857	mass	_	_	
8-15	858-860	of	_	_	
8-16	861-862	9	_	_	
8-17	863-868	grams	_	_	
8-18	868-869	.	_	_	

#Text=The most common surgical procedure to correct this urinary blockage or retention and other symptoms of benign prostate diseases is the trans-urethral resection of the prostate (TURP).
9-1	870-873	The	_	_	
9-2	874-878	most	_	_	
9-3	879-885	common	_	_	
9-4	886-894	surgical	_	_	
9-5	895-904	procedure	_	_	
9-6	905-907	to	_	_	
9-7	908-915	correct	_	_	
9-8	916-920	this	_	_	
9-9	921-928	urinary	_	_	
9-10	929-937	blockage	_	_	
9-11	938-940	or	_	_	
9-12	941-950	retention	_	_	
9-13	951-954	and	_	_	
9-14	955-960	other	_	_	
9-15	961-969	symptoms	_	_	
9-16	970-972	of	_	_	
9-17	973-979	benign	_	_	
9-18	980-988	prostate	_	_	
9-19	989-997	diseases	_	_	
9-20	998-1000	is	_	_	
9-21	1001-1004	the	_	_	
9-22	1005-1019	trans-urethral	_	_	
9-23	1020-1029	resection	_	_	
9-24	1030-1032	of	_	_	
9-25	1033-1036	the	_	_	
9-26	1037-1045	prostate	_	_	
9-27	1046-1047	(	_	_	
9-28	1047-1051	TURP	_	_	
9-29	1051-1052	)	_	_	
9-30	1052-1053	.	_	_	

#Text=The TURP procedure normally involves the surgical removal of about 15 to 20 grams of prostate tissue along the urethra passage inside the length of the prostate gland.
10-1	1054-1057	The	_	_	
10-2	1058-1062	TURP	_	_	
10-3	1063-1072	procedure	_	_	
10-4	1073-1081	normally	_	_	
10-5	1082-1090	involves	_	_	
10-6	1091-1094	the	_	_	
10-7	1095-1103	surgical	_	_	
10-8	1104-1111	removal	_	_	
10-9	1112-1114	of	_	_	
10-10	1115-1120	about	_	_	
10-11	1121-1123	15	_	_	
10-12	1124-1126	to	_	_	
10-13	1127-1129	20	_	_	
10-14	1130-1135	grams	_	_	
10-15	1136-1138	of	_	_	
10-16	1139-1147	prostate	_	_	
10-17	1148-1154	tissue	_	_	
10-18	1155-1160	along	_	_	
10-19	1161-1164	the	_	_	
10-20	1165-1172	urethra	_	_	
10-21	1173-1180	passage	_	_	
10-22	1181-1187	inside	_	_	
10-23	1188-1191	the	_	_	
10-24	1192-1198	length	_	_	
10-25	1199-1201	of	_	_	
10-26	1202-1205	the	_	_	
10-27	1206-1214	prostate	_	_	
10-28	1215-1220	gland	_	_	
10-29	1220-1221	.	_	_	

#Text=Thus, less tissue is treated by the heat treatment in the first session, than is surgically removed to resolve the symptoms.
11-1	1222-1226	Thus	_	_	
11-2	1226-1227	,	_	_	
11-3	1228-1232	less	_	_	
11-4	1233-1239	tissue	_	_	
11-5	1240-1242	is	_	_	
11-6	1243-1250	treated	_	_	
11-7	1251-1253	by	_	_	
11-8	1254-1257	the	_	_	
11-9	1258-1262	heat	_	_	
11-10	1263-1272	treatment	_	_	
11-11	1273-1275	in	_	_	
11-12	1276-1279	the	_	_	
11-13	1280-1285	first	_	_	
11-14	1286-1293	session	_	_	
11-15	1293-1294	,	_	_	
11-16	1295-1299	than	_	_	
11-17	1300-1302	is	_	_	
11-18	1303-1313	surgically	_	_	
11-19	1314-1321	removed	_	_	
11-20	1322-1324	to	_	_	
11-21	1325-1332	resolve	_	_	
11-22	1333-1336	the	_	_	
11-23	1337-1345	symptoms	_	_	
11-24	1345-1346	.	_	_	

#Text=After the first treatment with current methods, some of the prostate tissues become necrotic and begin to recede by the body's removal of the dead cells.
12-1	1347-1352	After	_	_	
12-2	1353-1356	the	_	_	
12-3	1357-1362	first	_	_	
12-4	1363-1372	treatment	_	_	
12-5	1373-1377	with	_	_	
12-6	1378-1385	current	_	_	
12-7	1386-1393	methods	_	_	
12-8	1393-1394	,	_	_	
12-9	1395-1399	some	_	_	
12-10	1400-1402	of	_	_	
12-11	1403-1406	the	_	_	
12-12	1407-1415	prostate	_	_	
12-13	1416-1423	tissues	_	_	
12-14	1424-1430	become	_	_	
12-15	1431-1439	necrotic	_	_	
12-16	1440-1443	and	_	_	
12-17	1444-1449	begin	_	_	
12-18	1450-1452	to	_	_	
12-19	1453-1459	recede	_	_	
12-20	1460-1462	by	_	_	
12-21	1463-1466	the	_	_	
12-22	1467-1473	body's	_	_	
12-23	1474-1481	removal	_	_	
12-24	1482-1484	of	_	_	
12-25	1485-1488	the	_	_	
12-26	1489-1493	dead	_	_	
12-27	1494-1499	cells	_	_	
12-28	1499-1500	.	_	_	

#Text=By the next heat treatment several days later, some of the original tissue is most likely not present.
13-1	1501-1503	By	_	_	
13-2	1504-1507	the	_	_	
13-3	1508-1512	next	_	_	
13-4	1513-1517	heat	_	_	
13-5	1518-1527	treatment	_	_	
13-6	1528-1535	several	_	_	
13-7	1536-1540	days	_	_	
13-8	1541-1546	later	_	_	
13-9	1546-1547	,	_	_	
13-10	1548-1552	some	_	_	
13-11	1553-1555	of	_	_	
13-12	1556-1559	the	_	_	
13-13	1560-1568	original	_	_	
13-14	1569-1575	tissue	_	_	
13-15	1576-1578	is	_	_	
13-16	1579-1583	most	_	_	
13-17	1584-1590	likely	_	_	
13-18	1591-1594	not	_	_	
13-19	1595-1602	present	_	_	
13-20	1602-1603	.	_	_	

#Text=This enables a second heat treatment to adequately heat tissues which were beyond the heating depth of the first treatment.
14-1	1604-1608	This	_	_	
14-2	1609-1616	enables	_	_	
14-3	1617-1618	a	_	_	
14-4	1619-1625	second	_	_	
14-5	1626-1630	heat	_	_	
14-6	1631-1640	treatment	_	_	
14-7	1641-1643	to	_	_	
14-8	1644-1654	adequately	_	_	
14-9	1655-1659	heat	_	_	
14-10	1660-1667	tissues	_	_	
14-11	1668-1673	which	_	_	
14-12	1674-1678	were	_	_	
14-13	1679-1685	beyond	_	_	
14-14	1686-1689	the	_	_	
14-15	1690-1697	heating	_	_	
14-16	1698-1703	depth	_	_	
14-17	1704-1706	of	_	_	
14-18	1707-1710	the	_	_	
14-19	1711-1716	first	_	_	
14-20	1717-1726	treatment	_	_	
14-21	1726-1727	.	_	_	

#Text=Thus, repeated heating treatments are required to eventually treat sufficient tissues to obtain the therapeutic effect and benefit as is provided by the surgical method of (TURP).
15-1	1728-1732	Thus	_	_	
15-2	1732-1733	,	_	_	
15-3	1734-1742	repeated	_	_	
15-4	1743-1750	heating	_	_	
15-5	1751-1761	treatments	_	_	
15-6	1762-1765	are	_	_	
15-7	1766-1774	required	_	_	
15-8	1775-1777	to	_	_	
15-9	1778-1788	eventually	_	_	
15-10	1789-1794	treat	_	_	
15-11	1795-1805	sufficient	_	_	
15-12	1806-1813	tissues	_	_	
15-13	1814-1816	to	_	_	
15-14	1817-1823	obtain	_	_	
15-15	1824-1827	the	_	_	
15-16	1828-1839	therapeutic	_	_	
15-17	1840-1846	effect	_	_	
15-18	1847-1850	and	_	_	
15-19	1851-1858	benefit	_	_	
15-20	1859-1861	as	_	_	
15-21	1862-1864	is	_	_	
15-22	1865-1873	provided	_	_	
15-23	1874-1876	by	_	_	
15-24	1877-1880	the	_	_	
15-25	1881-1889	surgical	_	_	
15-26	1890-1896	method	_	_	
15-27	1897-1899	of	_	_	
15-28	1900-1901	(	_	_	
15-29	1901-1905	TURP	_	_	
15-30	1905-1906	)	_	_	
15-31	1906-1907	.	_	_	

#Text=By using the circulating fluid cooling within the urethra during microwave treatment, the depth of the therapeutic heating is increased because more power can be radiated without causing excessive temperatures.
16-1	1908-1910	By	_	_	
16-2	1911-1916	using	_	_	
16-3	1917-1920	the	_	_	
16-4	1921-1932	circulating	_	_	
16-5	1933-1938	fluid	_	_	
16-6	1939-1946	cooling	_	_	
16-7	1947-1953	within	_	_	
16-8	1954-1957	the	_	_	
16-9	1958-1965	urethra	_	_	
16-10	1966-1972	during	_	_	
16-11	1973-1982	microwave	_	_	
16-12	1983-1992	treatment	_	_	
16-13	1992-1993	,	_	_	
16-14	1994-1997	the	_	_	
16-15	1998-2003	depth	_	_	
16-16	2004-2006	of	_	_	
16-17	2007-2010	the	_	_	
16-18	2011-2022	therapeutic	_	_	
16-19	2023-2030	heating	_	_	
16-20	2031-2033	is	_	_	
16-21	2034-2043	increased	_	_	
16-22	2044-2051	because	_	_	
16-23	2052-2056	more	_	_	
16-24	2057-2062	power	_	_	
16-25	2063-2066	can	_	_	
16-26	2067-2069	be	_	_	
16-27	2070-2078	radiated	_	_	
16-28	2079-2086	without	_	_	
16-29	2087-2094	causing	_	_	
16-30	2095-2104	excessive	_	_	
16-31	2105-2117	temperatures	_	_	
16-32	2117-2118	.	_	_	

#Text=Excessive temperature would certainly contribute to power limiting pain, and may contribute to undesirable toxicity.
17-1	2119-2128	Excessive	_	_	
17-2	2129-2140	temperature	_	_	
17-3	2141-2146	would	_	_	
17-4	2147-2156	certainly	_	_	
17-5	2157-2167	contribute	_	_	
17-6	2168-2170	to	_	_	
17-7	2171-2176	power	_	_	
17-8	2177-2185	limiting	_	_	
17-9	2186-2190	pain	_	_	
17-10	2190-2191	,	_	_	
17-11	2192-2195	and	_	_	
17-12	2196-2199	may	_	_	
17-13	2200-2210	contribute	_	_	
17-14	2211-2213	to	_	_	
17-15	2214-2225	undesirable	_	_	
17-16	2226-2234	toxicity	_	_	
17-17	2234-2235	.	_	_	

#Text=The volume of tissue which can therefore be treated to therapeutic temperature levels in the first treatment is about 22 cm.sup.3, which is a mass of 22 grams of tissue.
18-1	2236-2239	The	_	_	
18-2	2240-2246	volume	_	_	
18-3	2247-2249	of	_	_	
18-4	2250-2256	tissue	_	_	
18-5	2257-2262	which	_	_	
18-6	2263-2266	can	_	_	
18-7	2267-2276	therefore	_	_	
18-8	2277-2279	be	_	_	
18-9	2280-2287	treated	_	_	
18-10	2288-2290	to	_	_	
18-11	2291-2302	therapeutic	_	_	
18-12	2303-2314	temperature	_	_	
18-13	2315-2321	levels	_	_	
18-14	2322-2324	in	_	_	
18-15	2325-2328	the	_	_	
18-16	2329-2334	first	_	_	
18-17	2335-2344	treatment	_	_	
18-18	2345-2347	is	_	_	
18-19	2348-2353	about	_	_	
18-20	2354-2356	22	_	_	
18-21	2357-2363	cm.sup	_	_	
18-22	2363-2365	.3	_	_	
18-23	2365-2366	,	_	_	
18-24	2367-2372	which	_	_	
18-25	2373-2375	is	_	_	
18-26	2376-2377	a	_	_	
18-27	2378-2382	mass	_	_	
18-28	2383-2385	of	_	_	
18-29	2386-2388	22	_	_	
18-30	2389-2394	grams	_	_	
18-31	2395-2397	of	_	_	
18-32	2398-2404	tissue	_	_	
18-33	2404-2405	.	_	_	

#Text=This is slightly over that normally resected by a TURP.
19-1	2406-2410	This	_	_	
19-2	2411-2413	is	_	_	
19-3	2414-2422	slightly	_	_	
19-4	2423-2427	over	_	_	
19-5	2428-2432	that	_	_	
19-6	2433-2441	normally	_	_	
19-7	2442-2450	resected	_	_	
19-8	2451-2453	by	_	_	
19-9	2454-2455	a	_	_	
19-10	2456-2460	TURP	_	_	
19-11	2460-2461	.	_	_	

#Text=Thus, the method of cooling within the prostate urethra enables the complete target tissue mass along the prostate urethra to be adequately heated in just one heating session.
20-1	2462-2466	Thus	_	_	
20-2	2466-2467	,	_	_	
20-3	2468-2471	the	_	_	
20-4	2472-2478	method	_	_	
20-5	2479-2481	of	_	_	
20-6	2482-2489	cooling	_	_	
20-7	2490-2496	within	_	_	
20-8	2497-2500	the	_	_	
20-9	2501-2509	prostate	_	_	
20-10	2510-2517	urethra	_	_	
20-11	2518-2525	enables	_	_	
20-12	2526-2529	the	_	_	
20-13	2530-2538	complete	_	_	
20-14	2539-2545	target	_	_	
20-15	2546-2552	tissue	_	_	
20-16	2553-2557	mass	_	_	
20-17	2558-2563	along	_	_	
20-18	2564-2567	the	_	_	
20-19	2568-2576	prostate	_	_	
20-20	2577-2584	urethra	_	_	
20-21	2585-2587	to	_	_	
20-22	2588-2590	be	_	_	
20-23	2591-2601	adequately	_	_	
20-24	2602-2608	heated	_	_	
20-25	2609-2611	in	_	_	
20-26	2612-2616	just	_	_	
20-27	2617-2620	one	_	_	
20-28	2621-2628	heating	_	_	
20-29	2629-2636	session	_	_	
20-30	2636-2637	.	_	_	

#Text=To provide for a repeatable and safe therapy, it is important to provide sufficient power to reach these therapeutic levels and maintain these temperatures for typically about 60 minutes.
21-1	2638-2640	To	_	_	
21-2	2641-2648	provide	_	_	
21-3	2649-2652	for	_	_	
21-4	2653-2654	a	_	_	
21-5	2655-2665	repeatable	_	_	
21-6	2666-2669	and	_	_	
21-7	2670-2674	safe	_	_	
21-8	2675-2682	therapy	_	_	
21-9	2682-2683	,	_	_	
21-10	2684-2686	it	_	_	
21-11	2687-2689	is	_	_	
21-12	2690-2699	important	_	_	
21-13	2700-2702	to	_	_	
21-14	2703-2710	provide	_	_	
21-15	2711-2721	sufficient	_	_	
21-16	2722-2727	power	_	_	
21-17	2728-2730	to	_	_	
21-18	2731-2736	reach	_	_	
21-19	2737-2742	these	_	_	
21-20	2743-2754	therapeutic	_	_	
21-21	2755-2761	levels	_	_	
21-22	2762-2765	and	_	_	
21-23	2766-2774	maintain	_	_	
21-24	2775-2780	these	_	_	
21-25	2781-2793	temperatures	_	_	
21-26	2794-2797	for	_	_	
21-27	2798-2807	typically	_	_	
21-28	2808-2813	about	_	_	
21-29	2814-2816	60	_	_	
21-30	2817-2824	minutes	_	_	
21-31	2824-2825	.	_	_	

#Text=Higher temperatures would enable shorter times, but patient pain may prevent temperatures in excess of about 48.degree.
22-1	2826-2832	Higher	_	_	
22-2	2833-2845	temperatures	_	_	
22-3	2846-2851	would	_	_	
22-4	2852-2858	enable	_	_	
22-5	2859-2866	shorter	_	_	
22-6	2867-2872	times	_	_	
22-7	2872-2873	,	_	_	
22-8	2874-2877	but	_	_	
22-9	2878-2885	patient	_	_	
22-10	2886-2890	pain	_	_	
22-11	2891-2894	may	_	_	
22-12	2895-2902	prevent	_	_	
22-13	2903-2915	temperatures	_	_	
22-14	2916-2918	in	_	_	
22-15	2919-2925	excess	_	_	
22-16	2926-2928	of	_	_	
22-17	2929-2934	about	_	_	
22-18	2935-2937	48	_	_	
22-19	2937-2938	.	_	_	
22-20	2938-2944	degree	_	_	
22-21	2944-2945	.	_	_	

#Text=C.
23-1	2946-2947	C	_	_	
23-2	2947-2948	.	_	_	

#Text=It is possible to incorporate temperature sensors in the applicator to attempt to estimate tissue temperature, but this would also require monitoring to the radiated power and require performing occasional tissue cool-down measurements to estimate the effect of blood flow, tissue thermal conduction, and bolus cooling effects.
24-1	2949-2951	It	_	_	
24-2	2952-2954	is	_	_	
24-3	2955-2963	possible	_	_	
24-4	2964-2966	to	_	_	
24-5	2967-2978	incorporate	_	_	
24-6	2979-2990	temperature	_	_	
24-7	2991-2998	sensors	_	_	
24-8	2999-3001	in	_	_	
24-9	3002-3005	the	_	_	
24-10	3006-3016	applicator	_	_	
24-11	3017-3019	to	_	_	
24-12	3020-3027	attempt	_	_	
24-13	3028-3030	to	_	_	
24-14	3031-3039	estimate	_	_	
24-15	3040-3046	tissue	_	_	
24-16	3047-3058	temperature	_	_	
24-17	3058-3059	,	_	_	
24-18	3060-3063	but	_	_	
24-19	3064-3068	this	_	_	
24-20	3069-3074	would	_	_	
24-21	3075-3079	also	_	_	
24-22	3080-3087	require	_	_	
24-23	3088-3098	monitoring	_	_	
24-24	3099-3101	to	_	_	
24-25	3102-3105	the	_	_	
24-26	3106-3114	radiated	_	_	
24-27	3115-3120	power	_	_	
24-28	3121-3124	and	_	_	
24-29	3125-3132	require	_	_	
24-30	3133-3143	performing	_	_	
24-31	3144-3154	occasional	_	_	
24-32	3155-3161	tissue	_	_	
24-33	3162-3171	cool-down	_	_	
24-34	3172-3184	measurements	_	_	
24-35	3185-3187	to	_	_	
24-36	3188-3196	estimate	_	_	
24-37	3197-3200	the	_	_	
24-38	3201-3207	effect	_	_	
24-39	3208-3210	of	_	_	
24-40	3211-3216	blood	_	_	
24-41	3217-3221	flow	_	_	
24-42	3221-3222	,	_	_	
24-43	3223-3229	tissue	_	_	
24-44	3230-3237	thermal	_	_	
24-45	3238-3248	conduction	_	_	
24-46	3248-3249	,	_	_	
24-47	3250-3253	and	_	_	
24-48	3254-3259	bolus	_	_	
24-49	3260-3267	cooling	_	_	
24-50	3268-3275	effects	_	_	
24-51	3275-3276	.	_	_	

#Text=This is not expected to be as reliable in all patients as compared with a direct temperature measurement.
25-1	3277-3281	This	_	_	
25-2	3282-3284	is	_	_	
25-3	3285-3288	not	_	_	
25-4	3289-3297	expected	_	_	
25-5	3298-3300	to	_	_	
25-6	3301-3303	be	_	_	
25-7	3304-3306	as	_	_	
25-8	3307-3315	reliable	_	_	
25-9	3316-3318	in	_	_	
25-10	3319-3322	all	_	_	
25-11	3323-3331	patients	_	_	
25-12	3332-3334	as	_	_	
25-13	3335-3343	compared	_	_	
25-14	3344-3348	with	_	_	
25-15	3349-3350	a	_	_	
25-16	3351-3357	direct	_	_	
25-17	3358-3369	temperature	_	_	
25-18	3370-3381	measurement	_	_	
25-19	3381-3382	.	_	_	

#Text=The preferred method to measure the prostate tissue temperature is by using the heating applicator in a receive mode to direct the thermal noise in the heated prostate region into a microwave or US radiometer.
26-1	3383-3386	The	_	_	
26-2	3387-3396	preferred	_	_	
26-3	3397-3403	method	_	_	
26-4	3404-3406	to	_	_	
26-5	3407-3414	measure	_	_	
26-6	3415-3418	the	_	_	
26-7	3419-3427	prostate	_	_	
26-8	3428-3434	tissue	_	_	
26-9	3435-3446	temperature	_	_	
26-10	3447-3449	is	_	_	
26-11	3450-3452	by	_	_	
26-12	3453-3458	using	_	_	
26-13	3459-3462	the	_	_	
26-14	3463-3470	heating	_	_	
26-15	3471-3481	applicator	_	_	
26-16	3482-3484	in	_	_	
26-17	3485-3486	a	_	_	
26-18	3487-3494	receive	_	_	
26-19	3495-3499	mode	_	_	
26-20	3500-3502	to	_	_	
26-21	3503-3509	direct	_	_	
26-22	3510-3513	the	_	_	
26-23	3514-3521	thermal	_	_	
26-24	3522-3527	noise	_	_	
26-25	3528-3530	in	_	_	
26-26	3531-3534	the	_	_	
26-27	3535-3541	heated	_	_	
26-28	3542-3550	prostate	_	_	
26-29	3551-3557	region	_	_	
26-30	3558-3562	into	_	_	
26-31	3563-3564	a	_	_	
26-32	3565-3574	microwave	_	_	
26-33	3575-3577	or	_	_	
26-34	3578-3580	US	_	_	
26-35	3581-3591	radiometer	_	_	
26-36	3591-3592	.	_	_	

#Text=The temperature measurements of the radiometer provide a measurement which is directly related to the temperature within the prostate tissue volume corresponding to the heating volume.
27-1	3593-3596	The	_	_	
27-2	3597-3608	temperature	_	_	
27-3	3609-3621	measurements	_	_	
27-4	3622-3624	of	_	_	
27-5	3625-3628	the	_	_	
27-6	3629-3639	radiometer	_	_	
27-7	3640-3647	provide	_	_	
27-8	3648-3649	a	_	_	
27-9	3650-3661	measurement	_	_	
27-10	3662-3667	which	_	_	
27-11	3668-3670	is	_	_	
27-12	3671-3679	directly	_	_	
27-13	3680-3687	related	_	_	
27-14	3688-3690	to	_	_	
27-15	3691-3694	the	_	_	
27-16	3695-3706	temperature	_	_	
27-17	3707-3713	within	_	_	
27-18	3714-3717	the	_	_	
27-19	3718-3726	prostate	_	_	
27-20	3727-3733	tissue	_	_	
27-21	3734-3740	volume	_	_	
27-22	3741-3754	corresponding	_	_	
27-23	3755-3757	to	_	_	
27-24	3758-3761	the	_	_	
27-25	3762-3769	heating	_	_	
27-26	3770-3776	volume	_	_	
27-27	3776-3777	.	_	_	

#Text=This measurement is comprised of adding the temperature signals from the various tissue cells within the applicator's heating field.
28-1	3778-3782	This	_	_	
28-2	3783-3794	measurement	_	_	
28-3	3795-3797	is	_	_	
28-4	3798-3807	comprised	_	_	
28-5	3808-3810	of	_	_	
28-6	3811-3817	adding	_	_	
28-7	3818-3821	the	_	_	
28-8	3822-3833	temperature	_	_	
28-9	3834-3841	signals	_	_	
28-10	3842-3846	from	_	_	
28-11	3847-3850	the	_	_	
28-12	3851-3858	various	_	_	
28-13	3859-3865	tissue	_	_	
28-14	3866-3871	cells	_	_	
28-15	3872-3878	within	_	_	
28-16	3879-3882	the	_	_	
28-17	3883-3895	applicator's	_	_	
28-18	3896-3903	heating	_	_	
28-19	3904-3909	field	_	_	
28-20	3909-3910	.	_	_	

#Text=Therefore, this measurement is like having thousands of individual temperature points which are measured and then added together to provide an indication of the average temperatures within the heated region.
29-1	3911-3920	Therefore	*[1]	30-1[2_1]	
29-2	3920-3921	,	*[1]	_	
29-3	3922-3926	this	*[1]	_	
29-4	3927-3938	measurement	*[1]	_	
29-5	3939-3941	is	*[1]	_	
29-6	3942-3946	like	*[1]	_	
29-7	3947-3953	having	*[1]	_	
29-8	3954-3963	thousands	*[1]	_	
29-9	3964-3966	of	*[1]	_	
29-10	3967-3977	individual	*[1]	_	
29-11	3978-3989	temperature	*[1]	_	
29-12	3990-3996	points	*[1]	_	
29-13	3997-4002	which	*[1]	_	
29-14	4003-4006	are	*[1]	_	
29-15	4007-4015	measured	*[1]	_	
29-16	4016-4019	and	*[1]	_	
29-17	4020-4024	then	*[1]	_	
29-18	4025-4030	added	*[1]	_	
29-19	4031-4039	together	*[1]	_	
29-20	4040-4042	to	*[1]	_	
29-21	4043-4050	provide	*[1]	_	
29-22	4051-4053	an	*[1]	_	
29-23	4054-4064	indication	*[1]	_	
29-24	4065-4067	of	*[1]	_	
29-25	4068-4071	the	*[1]	_	
29-26	4072-4079	average	*[1]	_	
29-27	4080-4092	temperatures	*[1]	_	
29-28	4093-4099	within	*[1]	_	
29-29	4100-4103	the	*[1]	_	
29-30	4104-4110	heated	*[1]	_	
29-31	4111-4117	region	*[1]	_	
29-32	4117-4118	.	*[1]	_	

#Text=This method does not measure the maximum or the minimum temperature in the heated tissue, but provides an accurate measure of the average tissue temperature within the treatment zone.
30-1	4119-4123	This	*[2]	_	
30-2	4124-4130	method	*[2]	_	
30-3	4131-4135	does	_	_	
30-4	4136-4139	not	_	_	
30-5	4140-4147	measure	_	_	
30-6	4148-4151	the	_	_	
30-7	4152-4159	maximum	_	_	
30-8	4160-4162	or	_	_	
30-9	4163-4166	the	_	_	
30-10	4167-4174	minimum	_	_	
30-11	4175-4186	temperature	_	_	
30-12	4187-4189	in	_	_	
30-13	4190-4193	the	_	_	
30-14	4194-4200	heated	_	_	
30-15	4201-4207	tissue	_	_	
30-16	4207-4208	,	_	_	
30-17	4209-4212	but	_	_	
30-18	4213-4221	provides	_	_	
30-19	4222-4224	an	_	_	
30-20	4225-4233	accurate	_	_	
30-21	4234-4241	measure	_	_	
30-22	4242-4244	of	_	_	
30-23	4245-4248	the	_	_	
30-24	4249-4256	average	_	_	
30-25	4257-4263	tissue	_	_	
30-26	4264-4275	temperature	_	_	
30-27	4276-4282	within	_	_	
30-28	4283-4286	the	_	_	
30-29	4287-4296	treatment	_	_	
30-30	4297-4301	zone	_	_	
30-31	4301-4302	.	_	_	

#Text=This new method enables the treatment of benign prostate disease to be efficiently treated with hyperthermia, where the tissue being treated is the same tissue which would have been surgically removed by a TURP.
31-1	4303-4307	This	_	_	
31-2	4308-4311	new	_	_	
31-3	4312-4318	method	_	_	
31-4	4319-4326	enables	_	_	
31-5	4327-4330	the	_	_	
31-6	4331-4340	treatment	_	_	
31-7	4341-4343	of	_	_	
31-8	4344-4350	benign	_	_	
31-9	4351-4359	prostate	_	_	
31-10	4360-4367	disease	_	_	
31-11	4368-4370	to	_	_	
31-12	4371-4373	be	_	_	
31-13	4374-4385	efficiently	_	_	
31-14	4386-4393	treated	_	_	
31-15	4394-4398	with	_	_	
31-16	4399-4411	hyperthermia	_	_	
31-17	4411-4412	,	_	_	
31-18	4413-4418	where	_	_	
31-19	4419-4422	the	_	_	
31-20	4423-4429	tissue	_	_	
31-21	4430-4435	being	_	_	
31-22	4436-4443	treated	_	_	
31-23	4444-4446	is	_	_	
31-24	4447-4450	the	_	_	
31-25	4451-4455	same	_	_	
31-26	4456-4462	tissue	_	_	
31-27	4463-4468	which	_	_	
31-28	4469-4474	would	_	_	
31-29	4475-4479	have	_	_	
31-30	4480-4484	been	_	_	
31-31	4485-4495	surgically	_	_	
31-32	4496-4503	removed	_	_	
31-33	4504-4506	by	_	_	
31-34	4507-4508	a	_	_	
31-35	4509-4513	TURP	_	_	
31-36	4513-4514	.	_	_	

#Text=In many patients there are severe side effects by the TURP procedure such as incontinence, retrograde ejaculation, impotency, and death.
32-1	4515-4517	In	_	_	
32-2	4518-4522	many	_	_	
32-3	4523-4531	patients	_	_	
32-4	4532-4537	there	_	_	
32-5	4538-4541	are	_	_	
32-6	4542-4548	severe	_	_	
32-7	4549-4553	side	_	_	
32-8	4554-4561	effects	_	_	
32-9	4562-4564	by	_	_	
32-10	4565-4568	the	_	_	
32-11	4569-4573	TURP	_	_	
32-12	4574-4583	procedure	_	_	
32-13	4584-4588	such	_	_	
32-14	4589-4591	as	_	_	
32-15	4592-4604	incontinence	_	_	
32-16	4604-4605	,	_	_	
32-17	4606-4616	retrograde	_	_	
32-18	4617-4628	ejaculation	_	_	
32-19	4628-4629	,	_	_	
32-20	4630-4639	impotency	_	_	
32-21	4639-4640	,	_	_	
32-22	4641-4644	and	_	_	
32-23	4645-4650	death	_	_	
32-24	4650-4651	.	_	_	

#Text=It is estimated that between 0.3 to 3% of the patients receiving the TURP surgical procedure die from either the procedure or by other factors related to the procedure.
33-1	4652-4654	It	_	_	
33-2	4655-4657	is	_	_	
33-3	4658-4667	estimated	_	_	
33-4	4668-4672	that	_	_	
33-5	4673-4680	between	_	_	
33-6	4681-4684	0.3	_	_	
33-7	4685-4687	to	_	_	
33-8	4688-4690	3%	_	_	
33-9	4691-4693	of	_	_	
33-10	4694-4697	the	_	_	
33-11	4698-4706	patients	_	_	
33-12	4707-4716	receiving	_	_	
33-13	4717-4720	the	_	_	
33-14	4721-4725	TURP	_	_	
33-15	4726-4734	surgical	_	_	
33-16	4735-4744	procedure	_	_	
33-17	4745-4748	die	_	_	
33-18	4749-4753	from	_	_	
33-19	4754-4760	either	_	_	
33-20	4761-4764	the	_	_	
33-21	4765-4774	procedure	_	_	
33-22	4775-4777	or	_	_	
33-23	4778-4780	by	_	_	
33-24	4781-4786	other	_	_	
33-25	4787-4794	factors	_	_	
33-26	4795-4802	related	_	_	
33-27	4803-4805	to	_	_	
33-28	4806-4809	the	_	_	
33-29	4810-4819	procedure	_	_	
33-30	4819-4820	.	_	_	

#Text=Many patients are poor surgical risks due to their age and poor health.
34-1	4821-4825	Many	_	_	
34-2	4826-4834	patients	_	_	
34-3	4835-4838	are	_	_	
34-4	4839-4843	poor	_	_	
34-5	4844-4852	surgical	_	_	
34-6	4853-4858	risks	_	_	
34-7	4859-4862	due	_	_	
34-8	4863-4865	to	_	_	
34-9	4866-4871	their	_	_	
34-10	4872-4875	age	_	_	
34-11	4876-4879	and	_	_	
34-12	4880-4884	poor	_	_	
34-13	4885-4891	health	_	_	
34-14	4891-4892	.	_	_	

#Text=The use of hyperthermia treatments as described herein, represent a non-surgical alternative therapy for the benign prostate disease.
35-1	4893-4896	The	_	_	
35-2	4897-4900	use	_	_	
35-3	4901-4903	of	_	_	
35-4	4904-4916	hyperthermia	_	_	
35-5	4917-4927	treatments	_	_	
35-6	4928-4930	as	_	_	
35-7	4931-4940	described	_	_	
35-8	4941-4947	herein	_	_	
35-9	4947-4948	,	_	_	
35-10	4949-4958	represent	_	_	
35-11	4959-4960	a	_	_	
35-12	4961-4973	non-surgical	_	_	
35-13	4974-4985	alternative	_	_	
35-14	4986-4993	therapy	_	_	
35-15	4994-4997	for	_	_	
35-16	4998-5001	the	_	_	
35-17	5002-5008	benign	_	_	
35-18	5009-5017	prostate	_	_	
35-19	5018-5025	disease	_	_	
35-20	5025-5026	.	_	_	

#Text=The optimal combined utilization of the urethra inserted radiating energy microwave source, the circulation cooling fluid in the urethra, the positioning and urine drainage system of the Foley catheter, and the microwave radiometry provides a very practical method to treat benign prostate disease.
36-1	5027-5030	The	_	_	
36-2	5031-5038	optimal	_	_	
36-3	5039-5047	combined	_	_	
36-4	5048-5059	utilization	_	_	
36-5	5060-5062	of	_	_	
36-6	5063-5066	the	_	_	
36-7	5067-5074	urethra	_	_	
36-8	5075-5083	inserted	_	_	
36-9	5084-5093	radiating	_	_	
36-10	5094-5100	energy	_	_	
36-11	5101-5110	microwave	_	_	
36-12	5111-5117	source	_	_	
36-13	5117-5118	,	_	_	
36-14	5119-5122	the	_	_	
36-15	5123-5134	circulation	_	_	
36-16	5135-5142	cooling	_	_	
36-17	5143-5148	fluid	_	_	
36-18	5149-5151	in	_	_	
36-19	5152-5155	the	_	_	
36-20	5156-5163	urethra	_	_	
36-21	5163-5164	,	_	_	
36-22	5165-5168	the	_	_	
36-23	5169-5180	positioning	_	_	
36-24	5181-5184	and	_	_	
36-25	5185-5190	urine	_	_	
36-26	5191-5199	drainage	_	_	
36-27	5200-5206	system	_	_	
36-28	5207-5209	of	_	_	
36-29	5210-5213	the	_	_	
36-30	5214-5219	Foley	_	_	
36-31	5220-5228	catheter	_	_	
36-32	5228-5229	,	_	_	
36-33	5230-5233	and	_	_	
36-34	5234-5237	the	_	_	
36-35	5238-5247	microwave	_	_	
36-36	5248-5258	radiometry	_	_	
36-37	5259-5267	provides	_	_	
36-38	5268-5269	a	_	_	
36-39	5270-5274	very	_	_	
36-40	5275-5284	practical	_	_	
36-41	5285-5291	method	_	_	
36-42	5292-5294	to	_	_	
36-43	5295-5300	treat	_	_	
36-44	5301-5307	benign	_	_	
36-45	5308-5316	prostate	_	_	
36-46	5317-5324	disease	_	_	
36-47	5324-5325	.	_	_	

#Text=It is also feasible that this method will be suitable for the treatment of malignant prostate disease.
37-1	5326-5328	It	_	_	
37-2	5329-5331	is	_	_	
37-3	5332-5336	also	_	_	
37-4	5337-5345	feasible	_	_	
37-5	5346-5350	that	_	_	
37-6	5351-5355	this	_	_	
37-7	5356-5362	method	_	_	
37-8	5363-5367	will	_	_	
37-9	5368-5370	be	_	_	
37-10	5371-5379	suitable	_	_	
37-11	5380-5383	for	_	_	
37-12	5384-5387	the	_	_	
37-13	5388-5397	treatment	_	_	
37-14	5398-5400	of	_	_	
37-15	5401-5410	malignant	_	_	
37-16	5411-5419	prostate	_	_	
37-17	5420-5427	disease	_	_	
37-18	5427-5428	.	_	_	

#Text=The malignant prostate disease normally involves a larger size mass requiring treatment than is possible with the urethra inserted applicators.
38-1	5429-5432	The	_	_	
38-2	5433-5442	malignant	_	_	
38-3	5443-5451	prostate	_	_	
38-4	5452-5459	disease	_	_	
38-5	5460-5468	normally	_	_	
38-6	5469-5477	involves	_	_	
38-7	5478-5479	a	_	_	
38-8	5480-5486	larger	_	_	
38-9	5487-5491	size	_	_	
38-10	5492-5496	mass	_	_	
38-11	5497-5506	requiring	_	_	
38-12	5507-5516	treatment	_	_	
38-13	5517-5521	than	_	_	
38-14	5522-5524	is	_	_	
38-15	5525-5533	possible	_	_	
38-16	5534-5538	with	_	_	
38-17	5539-5542	the	_	_	
38-18	5543-5550	urethra	_	_	
38-19	5551-5559	inserted	_	_	
38-20	5560-5571	applicators	_	_	
38-21	5571-5572	.	_	_	

#Text=However, the increased treatment volume provided by this new method may enable some malignant prostate tumors to be effectively treated as long as the tumor resides within the therapeutic heating area which extends to about 0.8 cm away from the inserted applicator wall.
39-1	5573-5580	However	_	_	
39-2	5580-5581	,	_	_	
39-3	5582-5585	the	_	_	
39-4	5586-5595	increased	_	_	
39-5	5596-5605	treatment	_	_	
39-6	5606-5612	volume	_	_	
39-7	5613-5621	provided	_	_	
39-8	5622-5624	by	_	_	
39-9	5625-5629	this	_	_	
39-10	5630-5633	new	_	_	
39-11	5634-5640	method	_	_	
39-12	5641-5644	may	_	_	
39-13	5645-5651	enable	_	_	
39-14	5652-5656	some	_	_	
39-15	5657-5666	malignant	_	_	
39-16	5667-5675	prostate	_	_	
39-17	5676-5682	tumors	_	_	
39-18	5683-5685	to	_	_	
39-19	5686-5688	be	_	_	
39-20	5689-5700	effectively	_	_	
39-21	5701-5708	treated	_	_	
39-22	5709-5711	as	_	_	
39-23	5712-5716	long	_	_	
39-24	5717-5719	as	_	_	
39-25	5720-5723	the	_	_	
39-26	5724-5729	tumor	_	_	
39-27	5730-5737	resides	_	_	
39-28	5738-5744	within	_	_	
39-29	5745-5748	the	_	_	
39-30	5749-5760	therapeutic	_	_	
39-31	5761-5768	heating	_	_	
39-32	5769-5773	area	_	_	
39-33	5774-5779	which	_	_	
39-34	5780-5787	extends	_	_	
39-35	5788-5790	to	_	_	
39-36	5791-5796	about	_	_	
39-37	5797-5800	0.8	_	_	
39-38	5801-5803	cm	_	_	
39-39	5804-5808	away	_	_	
39-40	5809-5813	from	_	_	
39-41	5814-5817	the	_	_	
39-42	5818-5826	inserted	_	_	
39-43	5827-5837	applicator	_	_	
39-44	5838-5842	wall	_	_	
39-45	5842-5843	.	_	_	

#Text=Certainly if the urethral blockage through the prostate is caused by malignant growth, the use of this method to relieve the blockage symptom is also feasible, even though the intent would possibly not be to cure the cancer if the cancerous growth was larger than the heating volume.
40-1	5844-5853	Certainly	_	_	
40-2	5854-5856	if	_	_	
40-3	5857-5860	the	_	_	
40-4	5861-5869	urethral	_	_	
40-5	5870-5878	blockage	_	_	
40-6	5879-5886	through	_	_	
40-7	5887-5890	the	_	_	
40-8	5891-5899	prostate	_	_	
40-9	5900-5902	is	_	_	
40-10	5903-5909	caused	_	_	
40-11	5910-5912	by	_	_	
40-12	5913-5922	malignant	_	_	
40-13	5923-5929	growth	_	_	
40-14	5929-5930	,	_	_	
40-15	5931-5934	the	_	_	
40-16	5935-5938	use	_	_	
40-17	5939-5941	of	_	_	
40-18	5942-5946	this	_	_	
40-19	5947-5953	method	_	_	
40-20	5954-5956	to	_	_	
40-21	5957-5964	relieve	_	_	
40-22	5965-5968	the	_	_	
40-23	5969-5977	blockage	_	_	
40-24	5978-5985	symptom	_	_	
40-25	5986-5988	is	_	_	
40-26	5989-5993	also	_	_	
40-27	5994-6002	feasible	_	_	
40-28	6002-6003	,	_	_	
40-29	6004-6008	even	_	_	
40-30	6009-6015	though	_	_	
40-31	6016-6019	the	_	_	
40-32	6020-6026	intent	_	_	
40-33	6027-6032	would	_	_	
40-34	6033-6041	possibly	_	_	
40-35	6042-6045	not	_	_	
40-36	6046-6048	be	_	_	
40-37	6049-6051	to	_	_	
40-38	6052-6056	cure	_	_	
40-39	6057-6060	the	_	_	
40-40	6061-6067	cancer	_	_	
40-41	6068-6070	if	_	_	
40-42	6071-6074	the	_	_	
40-43	6075-6084	cancerous	_	_	
40-44	6085-6091	growth	_	_	
40-45	6092-6095	was	_	_	
40-46	6096-6102	larger	_	_	
40-47	6103-6107	than	_	_	
40-48	6108-6111	the	_	_	
40-49	6112-6119	heating	_	_	
40-50	6120-6126	volume	_	_	
40-51	6126-6127	.	_	_	

#Text=The use of ultrasound crystal cylinders is also considered feasible with this method which can operate as both energy transmitters as well as ultrasound radiometric temperature sensors.
41-1	6128-6131	The	_	_	
41-2	6132-6135	use	_	_	
41-3	6136-6138	of	_	_	
41-4	6139-6149	ultrasound	_	_	
41-5	6150-6157	crystal	_	_	
41-6	6158-6167	cylinders	_	_	
41-7	6168-6170	is	_	_	
41-8	6171-6175	also	_	_	
41-9	6176-6186	considered	_	_	
41-10	6187-6195	feasible	_	_	
41-11	6196-6200	with	_	_	
41-12	6201-6205	this	_	_	
41-13	6206-6212	method	_	_	
41-14	6213-6218	which	_	_	
41-15	6219-6222	can	_	_	
41-16	6223-6230	operate	_	_	
41-17	6231-6233	as	_	_	
41-18	6234-6238	both	_	_	
41-19	6239-6245	energy	_	_	
41-20	6246-6258	transmitters	_	_	
41-21	6259-6261	as	_	_	
41-22	6262-6266	well	_	_	
41-23	6267-6269	as	_	_	
41-24	6270-6280	ultrasound	_	_	
41-25	6281-6292	radiometric	_	_	
41-26	6293-6304	temperature	_	_	
41-27	6305-6312	sensors	_	_	
41-28	6312-6313	.	_	_	

#Text=In this form, the ultrasonic thermal energy radiated by the tissue within the ultrasound applicator's heating zone will be detected by the ultrasound radiometer.
42-1	6314-6316	In	_	_	
42-2	6317-6321	this	_	_	
42-3	6322-6326	form	_	_	
42-4	6326-6327	,	_	_	
42-5	6328-6331	the	_	_	
42-6	6332-6342	ultrasonic	_	_	
42-7	6343-6350	thermal	_	_	
42-8	6351-6357	energy	_	_	
42-9	6358-6366	radiated	_	_	
42-10	6367-6369	by	_	_	
42-11	6370-6373	the	_	_	
42-12	6374-6380	tissue	_	_	
42-13	6381-6387	within	_	_	
42-14	6388-6391	the	_	_	
42-15	6392-6402	ultrasound	_	_	
42-16	6403-6415	applicator's	_	_	
42-17	6416-6423	heating	_	_	
42-18	6424-6428	zone	_	_	
42-19	6429-6433	will	_	_	
42-20	6434-6436	be	_	_	
42-21	6437-6445	detected	_	_	
42-22	6446-6448	by	_	_	
42-23	6449-6452	the	_	_	
42-24	6453-6463	ultrasound	_	_	
42-25	6464-6474	radiometer	_	_	
42-26	6474-6475	.	_	_	

#Text=This would therefore be equivalent to the microwave urethral inserted applicator, but would operate at ultrasound frequencies.
43-1	6476-6480	This	_	_	
43-2	6481-6486	would	_	_	
43-3	6487-6496	therefore	_	_	
43-4	6497-6499	be	_	_	
43-5	6500-6510	equivalent	_	_	
43-6	6511-6513	to	_	_	
43-7	6514-6517	the	_	_	
43-8	6518-6527	microwave	_	_	
43-9	6528-6536	urethral	_	_	
43-10	6537-6545	inserted	_	_	
43-11	6546-6556	applicator	_	_	
43-12	6556-6557	,	_	_	
43-13	6558-6561	but	_	_	
43-14	6562-6567	would	_	_	
43-15	6568-6575	operate	_	_	
43-16	6576-6578	at	_	_	
43-17	6579-6589	ultrasound	_	_	
43-18	6590-6601	frequencies	_	_	
43-19	6601-6602	.	_	_	

#Text=Various ultrasound cylinders are commonly available such as from The EBL Company of Hartford, Conn.
44-1	6603-6610	Various	_	_	
44-2	6611-6621	ultrasound	_	_	
44-3	6622-6631	cylinders	_	_	
44-4	6632-6635	are	_	_	
44-5	6636-6644	commonly	_	_	
44-6	6645-6654	available	_	_	
44-7	6655-6659	such	_	_	
44-8	6660-6662	as	_	_	
44-9	6663-6667	from	_	_	
44-10	6668-6671	The	_	_	
44-11	6672-6675	EBL	_	_	
44-12	6676-6683	Company	_	_	
44-13	6684-6686	of	_	_	
44-14	6687-6695	Hartford	_	_	
44-15	6695-6696	,	_	_	
44-16	6697-6701	Conn	_	_	
44-17	6701-6702	.	_	_	

#Text=It is preferred that a longitudinal stack of ultrasound crystals be used to enable more flexibility and bending of the inserted crystals.
45-1	6703-6705	It	_	_	
45-2	6706-6708	is	_	_	
45-3	6709-6718	preferred	_	_	
45-4	6719-6723	that	_	_	
45-5	6724-6725	a	_	_	
45-6	6726-6738	longitudinal	_	_	
45-7	6739-6744	stack	_	_	
45-8	6745-6747	of	_	_	
45-9	6748-6758	ultrasound	_	_	
45-10	6759-6767	crystals	_	_	
45-11	6768-6770	be	_	_	
45-12	6771-6775	used	_	_	
45-13	6776-6778	to	_	_	
45-14	6779-6785	enable	_	_	
45-15	6786-6790	more	_	_	
45-16	6791-6802	flexibility	_	_	
45-17	6803-6806	and	_	_	
45-18	6807-6814	bending	_	_	
45-19	6815-6817	of	_	_	
45-20	6818-6821	the	_	_	
45-21	6822-6830	inserted	_	_	
45-22	6831-6839	crystals	_	_	
45-23	6839-6840	.	_	_	
